Development of multi-epitope mRNA vaccine against Clostridioides difficile using reverse vaccinology and immunoinformatics approaches
Synthetic and Systems Biotechnology · 2024-12 · 9 (4) · 667-683
DOI: 10.1016/j.synbio.2024.05.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthetic and Systems Biotechnology, 2024-12. Verfasst von Caixia Tan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infection Control Center, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clostridioides difficile (C. difficile), as the major pathogen of diarrhea in healthcare settings, has become increasingly prevalent within community populations, resulting in significant morbidity and mortality. However, the therapeutic options for Clostridioides difficile infection (CDI) remain limited, and as of now, no authorized vaccine is available to combat this disease. Therefore, the development of a novel vaccine against C. difficile is of paramount importance. In our study, the complete proteome sequences of 118 strains of C. difficile were downloaded and analyzed. We found four antigenic proteins that were highly conserved and can be used for epitope identification. We designed two vaccines, WLcd1 and WLcd2, that contain the ideal T-cell and B-cell epitopes, adjuvants, and the pan HLA DR-binding epitope (PADRE) sequences. The biophysical and chemical assessments of these vaccine candidates indicated that they were suitable for immunogenic applications. Molecular docking analyses revealed that WLcd1 bonded with higher affinity to Toll-like receptors (TLRs) than WLcd2. Furthermore, molecular dynamics (MD) simulations, performed using Gmx_MMPBSA v1.56, confirmed the binding stability of WLcd1 with TLR2 and TLR4. The preliminary findings suggested that this multi-epitope vaccine could be a promising candidate for protection against CDI; however, experimental studies are necessary to confirm these predictions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infection Control Center, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, China.
- National Clinical Research Center for Geriatric Disorders (XiangYa Hospital), Changsha, Hunan Province, 410008, China.
Zitieren
APA
Tan, C., Xiao, Y., Liu, T., Chen, S., Zhou, J., Zhang, S., Hu, Y., Wu, A., & Li, C. (2024). Development of multi-epitope mRNA vaccine against Clostridioides difficile using reverse vaccinology and immunoinformatics approaches. Synthetic and Systems Biotechnology, 9(4), 667-683. https://doi.org/10.1016/j.synbio.2024.05.008
Vancouver
Tan C, Xiao Y, Liu T, Chen S, Zhou J, Zhang S, et al. Development of multi-epitope mRNA vaccine against Clostridioides difficile using reverse vaccinology and immunoinformatics approaches. Synthetic and Systems Biotechnology. 2024;9(4):667-683. doi:10.1016/j.synbio.2024.05.008
BibTeX
@article{Tan2024,
author = {Tan, Caixia and Xiao, Yuanyuan and Liu, Ting and Chen, Siyao and Zhou, Juan and Zhang, Sisi and Hu, Yiran and Wu, Anhua and Li, Chunhui},
title = {Development of multi-epitope mRNA vaccine against Clostridioides difficile using reverse vaccinology and immunoinformatics approaches},
journal = {Synthetic and Systems Biotechnology},
year = {2024},
volume = {9},
number = {4},
pages = {667--683},
doi = {10.1016/j.synbio.2024.05.008}
}
EUVIMED